Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomised study to evaluate the impact of Ustekinumab on endothelial glycocalyx aortic elastic properties and vascular function compared to anti-TNFa agents or cyclosporine in patients with Psoriasis

Trial Profile

A Randomised study to evaluate the impact of Ustekinumab on endothelial glycocalyx aortic elastic properties and vascular function compared to anti-TNFa agents or cyclosporine in patients with Psoriasis

Completed
Phase of Trial: Phase IV

Latest Information Update: 14 Sep 2018

At a glance

  • Drugs Ustekinumab (Primary) ; Ciclosporin; Methotrexate; Tumour necrosis factor alpha inhibitors
  • Indications Psoriasis
  • Focus Therapeutic Use
  • Most Recent Events

    • 14 Sep 2018 New trial record
    • 29 Aug 2018 Results presented at the ESC Congress 2018: Annual Congress of the European Society of Cardiology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top